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Abstract
Background: Individuals heterozygous for germline ATM mutations have been reported to have an increased
risk for breast cancer but the role for ATM genetic variants for breast cancer risk has remained unclear. Recently,
a common ATM variant, ATMivs38 -8T>C in cis with the ATMex39 5557G>A (D1853N) variant, was suggested to
associate with bilateral breast cancer among familial breast cancer patients from Northern Finland. We have here
evaluated the 5557G>A and ivs38-8T>C variants in an extensive case-control association analysis. We also aimed
to investigate whether there are other ATM mutations or variants contributing to breast cancer risk in our
population.
Methods: Two common ATM variants, 5557G>A and ivs38-8T>C, previously suggested to associate with
bilateral breast cancer, were genotyped in an extensive set of 786 familial and 884 unselected breast cancer cases
as well as 708 healthy controls. We also screened the entire coding region and exon-intron boundaries of the
ATM gene in 47 familial breast cancer patients and constructed haplotypes of the patients. The identified variants
were also evaluated for increased breast cancer risk among additional breast cancer cases and controls.
Results: Neither of the two common variants, 5557G>A and ivs38-8T>C, nor any haplotype containing them,
was significantly associated with breast cancer risk, bilateral breast cancer or multiple primary cancers in any of
the patient groups or subgoups. Three rare missense alterations and one intronic change were each found in only
one patient of over 250 familial patients studied and not among controls. The fourth missense alteration studied
further was found with closely similar frequencies in over 600 familial cases and controls.
Conclusion: Altogether, our results suggest very minor effect, if any, of ATM genetic variants on familial breast
cancer in Southern Finland. Our results do not support association of the 5557G>A or ivs38-8T>C variant with
increased breast cancer risk or with bilateral breast cancer.
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Background
The ATM (Ataxia-Telangiectasia Mutated) kinase has an
essential role in maintaining genomic integrity. It is a key
activator of the cellular responses to DNA double-strand
breaks [1]. Mutations in the ATM gene cause ataxia-tel-
angiectasia (A-T) [2], a rare recessive disorder character-
ized by progressive neurodegeneration, cell cycle
checkpoint defects, radiosensitivity and increased risk of
cancer, particularly of lymphoid malignancies [3]. As radi-
ation exposure is associated with an increased risk of
breast cancer, the function of the ATM protein makes it a
good candidate for a role in breast cancer predisposition
[4]. The first suggestion that ATM might be a breast cancer
susceptibility gene came from studies reporting an
increased breast cancer risk among obligate heterozygous
mutation carriers in A-T families [5,6]. An increased risk
for malignancy, in particular, female breast cancer, among
individuals heterozygous for germline ATM  mutations
has been reported in many studies [7,8], but in a recent
study, the increased breast cancer risk of the heterozygous
mutation carriers in A-T families was seen only in the
mothers of the A-T patients [9], while another study
reported that the breast cancer risk in A-T families was
associated specifically with mutations located in the bind-
ing domains of the ATM protein [10]. A number of studies
have searched for germ line ATM mutations in breast can-
cer cases and/or compared the frequency of common var-
iants among breast cancer cases to population controls,
but the evidence regarding the role of ATM as a breast can-
cer susceptibility gene has been contradictory. Overall, the
frequency of ATM  mutations found in breast cancer
patients in the general population has been low, and
many of the ATM variants found are too rare to be evalu-
ated easily in case-control studies. Most of the studies
have also been too small to detect modest increases in risk
for the common ATM  variants, (reviewed in [4]). The
study of 270 Austrian breast and ovarian cancer families
reported a significant prevalence of ATM  mutations in
these families [11], whereas no ATM mutations associated
with increased breast cancer risk were found in 121 breast
or breast-ovarian cancer families from Northern Finland
[12]. However, a common variant, ATMivs38 -8T>C in cis
with the ATMex39 5557G>A (D1853N) variant, was sug-
gested to associate with bilateral breast cancer[12]. The
5557G>A variant has previously been reported in the
homozygous state to associate with enhanced clinical
radiosensitivity in breast cancer patients [13].
In this study, we have evaluated the 5557G>A and ivs38-
8T>C variants, suggested to associate with bilateral breast
cancer[12], for breast cancer risk and association with
bilateral breast cancer or multiple cancers in an extensive
set of 786 familial and 884 unselected Finnish breast can-
cer cases and 708 healthy controls. We further screened
the entire coding region and exon-intron boundaries of
the ATM gene from 47 familial breast cancer patients, in
order to determine the ATM haplotypes among the Finn-
ish breast cancer patients, and to investigate whether there
are other ATM  mutations or variants contributing to
breast cancer risk in Southern Finland.
Methods
Breast cancer patients and controls
We evaluated the common polymorphisms ATMex39
5557G>A (D1853N) and ATMivs38 -8T>C for breast can-
cer risk by genotyping those in a series of 786 familial
breast cancer patients, 884 unselected breast cancer cases
and 708 healthy female control subjects from the same
geographical region.
The familial breast cancer patients have been collected by
a systematic interview for family history at the Helsinki
University Central Hospital as previously described [14].
Of the 786 familial patients, the 284 patients (including
the 47 breast cancer patients screened for the whole gene
and the 237 cases studied also for the rare variants below)
have a stronger family history (three or more first or sec-
ond degree relatives with breast or ovarian cancer in the
family, including the proband), as verified through the
Finnish Cancer Registry and hospital records, and 502
breast cancer cases (368 of which were also studied for
ATMex10 998C>T (S333F)) have reported only a single
affected first-degree relative. BRCA1  and  BRCA2  muta-
tions have been excluded for all the familial patients with
the strong family history of cancer as well as for 291 cases
with one affected relative as previously described [15-17].
The series of 884 unselected breast cancer patients studied
were collected at the Department of Oncology, Helsinki
University Central Hospital during April 1997-March
1998 (described in detail in [18]) and January-June 2000
[19] and cover 79% of all consecutive, newly diagnosed
breast cancer cases during the collection periods.
The index patients from forty-seven BRCA1/2-negative
breast cancer or breast-ovarian cancer families (three or
more first or second degree relatives with breast or ovarian
cancer in the family, including the proband) were also
fully screened for germline variants throughout the cod-
ing regions and splice sites of the ATM gene. Thirteen of
these 47 index patients also had a family history of leuke-
mia and/or lymphoma.
The frequencies of five rare ATM germline variants identi-
fied (four missense alterations and one intronic change
known to lead to incorrect splicing of the ATM transcript
[20]) were further studied in an additional series of 237
index patients from non-BRCA1/2 breast cancer families
(three or more first or second degree relatives with breast
or ovarian cancer in the family, including the proband)
and 237 healthy population controls. One of the five rareBMC Cancer 2006, 6:209 http://www.biomedcentral.com/1471-2407/6/209
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variants, ATMex10 998C>T (S333F) residing on the same
haplotype with the 5557G>A and ivs38-8T>C variants,
was then further screened in additional 368 breast cancer
cases from families with two affected first-degree relatives,
and in 367 healthy controls.
All specimens were collected and analyzed with informed
consent and under protocols approved by ethics commit-
tees of the Departments of Obstetrics and Gynecology,
and Oncology, and the Ministry of Social Affairs and
Health in Finland.
Mutation analyses
The three variants (5557G>A, ivs38-8T>C and 998C>T)
were genotyped in extensive patient series and population
controls described above, using minisequencing (primer
extension [21]), Amplifluor™ fluorescent genotyping
(KBiosciences, Cambridge, UK [22]) or restriction frag-
ment length polymorphism analysis (RFLP): the ivs38-
8T>C change creates a restriction site for RsaI (New Eng-
land BioLabs, Beverly, MA, USA); for 998C>T a mutagen-
esis PCR-primer was designed that creates a restriction site
for  EcoRI (New England BioLabs, Beverly, MA, USA),
which is abolished by the 998C>T change. Carriers of the
ivs38-8T>C or 998C>T change could be detected in a 2%
or 3% agarose gel after RsaI or EcoRI digestion of the PCR-
products, respectively. All the samples found positive for
998C>T with RFLP were confirmed by direct sequencing.
For the ivs38-8T>C variant, all the positive cases were re-
analysed by RFLP and a sample of them were also con-
firmed by direct sequencing. For the 5557G>A variant, 50
samples were genotyped by two independent methods
(minisequencing and Amplifluor™ fluorescent genotyp-
ing). All the re-analysis and confirmation results were
consistent.
Genomic DNA from the 47 familial breast cancer patients
was screened for germline alterations in all coding exons
and exon-intron boundaries of ATM gene by denaturating
high-performance liquid chromatography [23] (dHPLC,
WAVE, Transgenomic Inc., Omaha, NE, USA). All samples
with an abnormal curve were re-amplified and sequenced
by direct sequencing using BigDye Terminator Cycle
Sequencing Kit and ABI 310 automated sequencer
(Applied Biosystems, Foster City, CA, USA). Five rare var-
iants found were further screened by dHPLC and all posi-
tive samples were verified by direct sequencing.
Bioinformatic and statistical analyses
Haplotypes were reconstructed using PHASE (version
2.1.1) [24]. The software implements a Bayesian statistical
method for reconstructing haplotypes based on popula-
tion genotype data [25,26]. SIFT-analysis [27,28] and
PolyPhen [29,30] were used to evaluate functional signif-
icance of the ATM missense variants found. SIFT program
calculates tolerance scores for amino acid changes based
on sequence alignment and conservation across protein
family or across evolutionary history. PolyPhen (=Poly-
morphism Phenotyping) predicts possible impact of an
amino acid substitution on the structure and function of
a human protein using straightforward physical and com-
parative considerations. The differences in variant fre-
quencies were analysed by Fisher's exact test (SPSS version
12.0 for Windows, SPSS Inc., Chicago, IL, USA). All p-val-
ues are two-sided, and due to multiple testing, p-value
<0.01 was considered significant. Estimates of statistical
power and ideal sample size were obtained using the
UCLA Department of Statistics power calculator [31,32]
and the SISA statistics calculator [33,34].
Results
The genotype distribution of the common ATMex39
5557G>A (D1853N) polymorphism studied was closely
similar in breast cancer cases and healthy controls, sug-
gesting no effect on breast cancer risk (Table 1.). No asso-
ciation of this polymorphism with bilateral breast cancer
or multiple cancers (breast cancer and at least one other
non-breast cancer) was seen among the familial or unse-
lected breast cancer cases (Table 2.). No association with
histopathologic features (tumor histology, grade, hor-
mone receptor status, TNM stage) of the breast tumors or
survival among the unselected breast cancer patients was
seen, either (data not shown). This alteration also
appeared well tolerated in SIFT (score 0.17) and PolyPhen
(benign) analysis.
No significant effect on breast cancer risk of the ATMivs38
-8T>C polymorphism was observed (Table 1.). It was not
associated with any histopathologic features of the breast
tumors or survival among unselected breast cancer
patients (data not shown). The ivs38-8T>C polymor-
phism was not significantly associated with the risk of
bilateral breast cancer among unselected or familial breast
cancer patients. Among the unselected breast cancer
patients, the ivs38-8T>C polymorphism tended to be
associated with an increased risk of multiple primary can-
cers (breast cancer and at least one other non-breast can-
cer) (OR 2.56, 95% CI 1.23–5.35, p = 0.02, Fisher's exact
test, Table 2.), but the result did not reach statistical signif-
icance and was not seen among the familial cases.
ATM sequence variants found in the full gene screen from
47 Finnish familial breast cancer patients as well as haplo-
types constructed with PHASE software are presented in
Table 3. Altogether 17 different sequence variants forming
17 different haplotypes were found. Seven of the variants
were intronic, four were silent nucleotide substitutions
and six were missense changes.BMC Cancer 2006, 6:209 http://www.biomedcentral.com/1471-2407/6/209
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The 5557G>A variant was present in altogether six haplo-
types (haplotypes 7, 8, 9, 10, 12 and 13 in Table 3.), and
three of them (haplotypes 8, 9 and 13 in Table 3.) con-
tained also the ivs38-8T>C variant. The haplotype 8 con-
tains only the combined variant 5557G>A, ivs38-8T>C,
whereas the haplotype 13 contains also the missense var-
iant 998C>T (S333F) in exon 10. To further evaluate this
haplotype the missense variant 998C>T was studied in
additional 368 breast cancer cases with a moderate family
history and in 367 healthy controls, as well as in 237
breast cancer cases with a stronger family history and in
237 healthy controls (see below). The third haplotype
(haplotype 9) containing the combined variant 5557G>A,
ivs38-8T>C included also the silent change ATMex32
4578C>T (P1526P), which was found in only 1/47 of our
fully screened cases.
Four rare missense alterations and one of the intronic
changes, ATMivs10 -6T>G, a known A-T mutation leading
to skipping of the exon eleven in the transcript [20], were
screened in additional series of 237 familial breast cancer
cases and 237 healthy controls. The frequencies of these
five variants in breast cancer cases and healthy controls are
presented in Table 4. None of the variants segregated with
cancer in the families studied. Only the index case with
998C>T (S333F) carried the variant in one family studied,
with three other affected sisters being non-carriers; for two
other families no additional samples were available. Sim-
ilarly, only the index cases carried the 1814A>G (H605R)
and ivs10-6T>G variants. For 1814A>G, three other
affected relatives (sister, cousin and her daughter) were
not carriers. For the ivs10-6T>G variant, the two other
affected in the family were not carriers whereas two of the
three healthy sisters (aged 63 and 73 years) of the index
case carried the variant. Unfortunately, no samples of
affected relatives were available for the 4424A>G
(Y1457C) and 6539G>T (G2180V) variant carrier cases.
The fifth rare missense alteration, ATMex15  2119T>C
(S707P), was not studied further as it has been extensively
studied previously [20,35-37], and the results do not sup-
port its association with breast cancer.
Discussion
The common polymorphism, ATMex39  5557G>A
(D1853N), has been reported in the homozygous state to
associate with enhanced clinical radiosensitivity in breast
cancer patients [13], suggesting that it might be consid-
ered as a risk factor predisposing to adverse reactions after
radiotherapy and supporting a possible functional effect
for this variant. Heikkinen et al. [12] recently reported
that the ATMivs38 -8T>C polymorphism occurring in cis
position with 5557G>A was associated with bilateral
breast cancer, among altogether 176 familial breast cancer
patients studied. The combined variant was found to asso-
ciate also with reduction of ATM protein level in lym-
phoblast cells. No aberrant transcripts were detected [12],
although it was hypothesized that the 5557G>A variant
previously suggested to affect an exonic splicing enhancer
element [11] together with the ivs38-8T>C change could
have some effect on the correct splicing of the exon 39.
Most recently, Langholz et al. [38] reported that the asso-
ciation of ivs38-8T>C with bilateral breast cancer could
not be replicated in the WECARE Study population of 708
asynchronous bilateral and 1397 unilateral breast cancer
patients. While this does not support the previously sug-
gested association of the variant with bilateral breast can-
cer, Langholz et al. [38] discussed the possibility that the
variants studied may not be the causative alleles but may
be contained in the same risk haplotype with other, pos-
sible risk alleles unique to the Finnish population. The
WECARE cases were also unselected for family history
while those in the study by Heikkinen et al. [12] belonged
Table 1: ATMex39 D1853N and ATMivs38(-8)T>C genotype frequencies among population controls and unselected and familial breast 
cancer patients, by family history
ATMex39 D1853N total DD DN NN OR (95% CI)* p
population controls 702 404 57.5% 260 37.0% 38 5.4%
unselected breast cancer patients 803 485 60.4% 285 35.5% 33 4.1% 0.89 (0.72–1.09) 0.27
familial breast cancer patients 778 469 60.3% 276 35.5% 33 4.2% 0.89 (0.73–1.10) 0.29
index with one affected first degree relative 502 309 61.6% 170 33.9% 23 4.6% 0.85 (0.67–1.07) 0.17
three or more affected in the family 276 160 58.0% 106 38.4% 10 3.6% 0.98 (0.74–1.30) 0.94
* compared to population controls, DN+NN vs. DD
ATMivs38(-8)T>C total TT TC OR (95% CI) p
population controls 708 668 94.4% 40 5.6%
unselected breast cancer patients 818 769 94.0% 49 6.0% 1.06 (0.69–1.64) 0.83
familial breast cancer patients 774 717 92.6% 57 7.4% 1.32 (0.87–2.02) 0.21
index with one affected first degree relative 495 455 91.9% 40 8.1% 1.47 (0.93–2.31) 0.10
three or more affected in the family 279 262 93.9% 17 6.1% 1.08 (0.60–1.95) 0.76BMC Cancer 2006, 6:209 http://www.biomedcentral.com/1471-2407/6/209
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to breast cancer families. In our study, including about
800 unselected as well as almost 800 familial Finnish
breast cancer cases, neither 5557G>A nor ivs38-8T>C, or
any haplotype containing these variants in the Finnish
population, was associated with breast cancer risk or bilat-
eral breast cancer in any of the patient groups or subgoups
studied. Among our familial breast cancer patients
screened for the whole ATM gene, both of the variants
5557G>A and ivs38-8T>C were present in altogether three
haplotypes (haplotypes 8, 9 and 13 in Table 3.). Our
results suggest that the haplotype 8, containing only the
combined variant 5557G>A, ivs38-8T>C, is not associated
with bilateral breast cancer. The haplotype 13 containing
also the missense variant 998C>T (S333F) in exon 10 is
far too rare to underlie the suggested association with
bilateral breast cancer [12]: only 6/652 (0.92%) familial
breast cancer patients carried this haplotype. The third
haplotype (haplotype 9) containing the combined variant
5557G>A, ivs38-8T>C included also the silent change
ATMex32 4578C>T (P1526P), which was found in only 1/
47 of our fully screened cases. This variant was not sug-
gested to be in linkage disequilibrium with other variants
in Northern Finland [12], nor in the HapMap database
[39], and it was not suggested to associate with bilateral
breast cancer [12]. Although the number of cases studied
for determining the haplotypes was only 47 (94 chromo-
somes), the 95% confidence intervals (0.000 – 0.039) for
undetected haplotypes (frequency 0.000) suggest a maxi-
mum combined frequency of 3.9% for undetected haplo-
types with a 95% probability. This suggests also that any
undetected haplotypes would have been rare and unlikely
to account for the proposed association of ivs38-8T>C
with bilateral breast cancer.
The carrier frequency of the ivs38-8T>C variant (or the
combined variant, as all the carriers of ivs38-8T>C also
carried 5557G>A) was marginally higher in familial breast
cancer patients, especially in those patients with only a
moderate family history of breast cancer (8.1%), than in
healthy controls (5.6%), but the difference does not reach
statistical significance. Given that the case-control tests for
the ivs38-8T>C variant yielded positive odds ratios, post
hoc calculations were performed to evaluate the statistical
power of our analysis. If the observed OR of 1.32 for
Table 2: Multiple cancer and bilateral breast cancer among unselected and familial breast cancer patients, by ATMex39 D1853N and 
ATMivs38(-8)T>C genotype
ATMex39 D1853N total DD DN NN OR (95% CI)* p
Unselected breast cancer patients 803 485 285 33
Bilateral 52 6.5% 37 7.6% 14 4.9% 1 3.0% 0.60 (0.32–1.11) 0.11
Unilateral 751 93.5% 448 92.4% 271 95.1% 32 97.0%
Multiple cancer 83 10.3% 51 10.5% 31 10.9% 1 3.0% 0.95 (0.60–1.52) 0.91
Breast cancer only 720 89.7% 434 89.5% 254 89.1% 32 97.0%
Familial breast cancer patients 778 469 276 33
Bilateral 86 11.1% 53 11.3% 30 10.9% 3 9.1% 0.94 (0.59–1.49) 0.82
Unilateral 692 88.9% 416 88.7% 246 89.1% 30 90.9%
Multiple cancer 89 11.4% 57 12.2% 29 10.5% 3 9.1% 0.84 (0.53–1.32) 0.49
Breast cancer only 689 88.6% 412 87.8% 247 89.5% 30 90.9%
*DN+NN vs. DD
ATMivs38(-8)T>C total TT TC OR (95% CI) p
Unselected breast cancer patients 818 769 49
Bilateral 49 6.0% 45 5.9% 4 8.2% 1.43 (0.49–4.15) 0.53
Unilateral 769 94.0% 724 94.1% 45 91.8%
Multiple cancer 80 9.8% 70 9.1% 10 20.4% 2.56 (1.23–5.35) 0.02
Breast cancer only 738 90.2% 699 90.1% 39 79.6%
Familial breast cancer patients 774 717 57
Bilateral 84 10.9% 78 10.9% 6 10.5% 0.96 (0.40–2.32) 1.0
Unilateral 690 89.1% 639 89.1% 51 89.5%
Multiple cancer 92 11.9% 85 11.9% 7 12.3% 1.04 (0.46–2.37) 0.83
Breast cancer only 682 88.1% 632 88.1% 50 87.7%B
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Table 3: ATM sequence variants and haplotypes found in 47 Finnish familial breast cancer patients
variant ex5 ex9 ex10** ex11** ex14** ex15 ex20 ex31** ex32 ex39a ex39b*** ex39c*** ex40 ex41 ex46 ex47** ex62
freq. 1/47 5/47 1/47 1/47 1/47 1/47 1/47 1/47 1/47 1/47 4/47 18/47* 1/47 1/47 2/47 1/47 2/47
freq. haplotype
0.65 1 TC C T A T - A C G T G G T T G A
0.01 2 TC C T A T - A C G T G G T T G C
0.01 3 TC C T A T - A C G T G G T T T A
0.02 4 TC C T A T - A C G T G G T C GA
0.01 5 TC C T A T - A C G T G A TT G C
0.01 6 TC C T A T - A C C TG G T T G A
0.15 7 TC C T A T - A C G T A GTT G A
0.02 8 TC C T A T - A C G CA GTT G A
0.01 9 TC C T A T - A T G CA GTT G A
0.01 10 TC C T A T - G CG T A GTT G A
0.01 11 TC C T G T- A CG T G G TT G A
0.01 12 TC C G AT -AC G T A GTT G A
0.01 13 TC T TA T - A C G CA GTT G A
0.01 14 T T CTA T A AC G T G G C TGA
0.03 15 T T CTA T - A C G T GG T T G A
0.01 16 T T CTA C -AC G T G G T TG A
0.01 17 C CC T A T - A C G TG G T T G A
variant nt change aa change rs-number
ex5 162T>C Y54Y 3218690
ex9 735C>T V245V 3218674#
ex10 998C>T S333F 28904919
ex11 ivs10(-6)T>G - -
ex14 1814A>G H605R -
ex15 2119T>C S707P 4986761#
ex20 ivs20(+28)insA - -
ex31 4424A>G Y1475C -
ex32 4578C>T P1526P 1800889#
ex39a ivs38(-15)G>C - 3092828
ex39b ivs38(-8)T>C - 3092829#
ex39c 5557G>A D1853N 1801516#
ex40 ivs40(+27)G>A - 3218686
ex41 5793T>C A1931A 3092910
ex46 ivs45(-54)T>C - -
ex47 6539G>T G2180V -
ex62 ivs 62(+8)A>C - -
# these SNPs have been studied in the HapMap project
* two homozygotes
** studied further in series of breast cancer cases and controls, see also Table 4.
*** studied further in series of breast cancer cases and controls, see also Table 1.BMC Cancer 2006, 6:209 http://www.biomedcentral.com/1471-2407/6/209
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familial breast cancer risk was assumed to reflect the
actual population risk for familial breast cancer, a sample
size of 2974 cases and controls would be required to reach
80% power to correctly reject the null hypothesis of no
association. The current sample size has only a 29%
power to detect a similar effect size. However, our study
had 80% power to detect an association with an odds
ratio of 1.70 or more among familial cases (with odds
ratio 2.86 for bilateral breast cancer and 2.77 for multiple
cancer) and 1.68 among unselected cases (with odds ratio
3.6 for bilateral breast cancer and 2.9 for multiple cancer),
at a significance threshold of 0.05. Our results do not sup-
port an association of the variants with increased breast
cancer risk in any of the patient groups studied, however,
small increases in risk cannot be excluded. However, our
results are consistent with those by Langholz et al. [38]
who also found no association of the 5557G>A/ivs38-
8T>C variant with bilateral breast cancer (OR = 1, 95% CI
0.6–1.5). The variants did not associate (together or
alone) with histopathologic features of the tumors, sur-
vival of the patients or the age of first breast cancer diag-
nosis among the unselected breast cancer patients, either
(data not shown).
As A-T patients have an increased risk for lymphoid malig-
nancies, we also evaluated whether the 5557G>A and
ivs38-8T>C variants (together or alone) associate with
family history of these malignancies. No such effect was
seen (data not shown). The variants were not significantly
associated with multiple primary tumors, either.
Screening of the whole coding region of the gene revealed
altogether 17 different sequence variants in the ATM gene
in the 47 familial breast cancer patients. Seventeen differ-
ent haplotypes were also seen, with haplotype frequency
0.65 for the major haplotype 1 with no ATM variation
present in the exonic and adjacent intronic regions stud-
ied. The two most common haplotypes (with frequencies
of 0.65 and 0.15) represented 80% of the haplotypes of
the patients studied here, and the three most common
haplotypes (the third with a frequency of 0.03) accounted
for 83% of all the haplotypes here. The haplotype distri-
bution in the ATM locus in the Finnish population seems
similar to other populations studied, where two to three
major ATM haplotypes representing >80% of the haplo-
types have been identified and suggested to explain the
majority of ATM  variation [13,40,41]. However, direct
comparison of the actual haplotypes is difficult as differ-
ent markers have been used in different studies for evalu-
ating the haplotypes, including also non-coding single
nucleotide polymorphisms (SNPs) in and around the
ATM locus. ATM haplotypes have been also reported to
associate with increased breast cancer risk in Korean pop-
ulation [42]; in that study, one coding and four intronic
SNPs were used for haplotype construction. The Interna-
tional HapMap Consortium [39,43] has genotyped 298
SNPs in the ATM containing region on chromosome 11,
including five of the SNPs identified here; ATMex9
735C>T (V245V), ATMex15 2119T>C (S707P), ATMex32
4578C>T (P1526P), ATMivs38  -8T>C and ATMex39
5557G>A (D1853N). When applying the criteria used by
the HapMap project in determining tag-SNPs (r2>0.80),
only one of the SNPs, 5557G>A, is in complete linkage
disequilibrium (LD) with other SNPs genotyped by the
HapMap project; rs3092991 and rs4988023 located in the
middle of the intron 20 and 35, respectively.
Of the 17 variants identified in this study, seven were
intronic, four were silent and six were missense changes.
All the intronic and silent changes have been reported pre-
viously. One of the silent changes, ATMex9  735C>T
(V245V), has previously been found to co-occur with
skipping of exon 9 in some A-T patients [44]. However,
other causative A-T mutations have more recently been
identified in these families (Børresen-Dale, unpublished).
In addition, the reported skipping of exon 9 was detected
only on cDNA and is seen occasionally probably because
the degradation of non-proofread transcripts has not
occurred, or it may be an artifact caused by mRNA insta-
bility (Børresen-Dale, unpublished). This silent change
was also reported to be more frequent in controls than in
breast cancer cases from Northern Finland [12]. Based on
these, this variant was not screened further in our study.
One of the intronic changes, ivs10-6T>G, a known A-T
mutation leading to incorrect splicing of the exon 11 and
premature truncation of the protein [20], has been sug-
gested to associate with breast cancer in different popula-
tions [11,45,46], but larger case-control studies have not
found a significant difference in frequencies between
breast cancer cases and healthy controls [47-49]. In our
study, ivs10-6T>G was found in one of 265 familial breast
Table 4: Frequencies of five ATM sequence variants in Finnish 
breast cancer cases and controls
variant cases controls SIFT PolyPhen
ex10 6/652 5/604
998C>T (S333F) 0.92% 0.83% 0.00 benign
ex11 1/265 0/228
ivs10-6T>G 0.38% 0.00%
ex14 1/253 0/232
1814A>G (H605R) 0.40% 0.00% 0.00 possibly damaging
ex31 1/273 0/234
4424A>G (Y1475C) 0.37% 0.00% 0.08 probably damaging
ex47 1/264 0/234
6539G>T (G2180V) 0.38% 0.00% 0.03 probably damagingBMC Cancer 2006, 6:209 http://www.biomedcentral.com/1471-2407/6/209
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cancer cases and not in 228 controls and did not segregate
with cancer in the family.
One of the five rare missense variants identified, 2119T>C
(S707P), has been very extensively evaluated for breast
cancer risk previously [20,35-37], and the results do not
support its association with breast cancer. All the four rare
missense variants studied further, 1814A>G (H605R),
4424A>G (Y1457C), 6539G>T (G2180V) and 998C>T
(S333F), may affect ATM function as suggested by bioin-
formatic analysis (Table 4.). Three of these variants were
very rare, each identified in only one out of >250 cases
while not in population controls. The 1814A>G variant
has previously been found also in a Danish breast cancer
patient (Børresen-Dale, unpublished), whereas the
4424A>G variant has been found in a healthy population
control but not among breast cancer patients [36]. To our
knowledge, the 6539G>T variant has not been reported
previously. Even if having functional effect on the ATM
protein and possibly being pathogenic, the rarity of these
variants limits any potential contribution to breast cancer
susceptibility. The 998C>T was found in 0.92% of the
cases and in 0.83% of the controls, not supporting an
association with breast cancer. We have previously inves-
tigated whether the seven A-T mutations found in Finnish
A-T families [44,50] are seen also among familial breast
cancer patients from Southern Finland. Only one of these
mutations, ATMex53 7570G>C (A2524P), was found in
one case among the 373 studied familial breast cancer
patients []. Altogether, these results suggest that possible
breast cancer associated ATM mutations are very rare in
breast cancer families from Southern Finland. However,
whether rare ATM mutations, estimated to be present in
about 0.4%–1% of the population [8,51], confer an
increased breast cancer risk in the population, is beyond
the scope of this study and has not been evaluated at a
large scale in other studies yet either. Due to the rarity of
such variants, very large population-based case-control
studies will be required [52].
Conclusion
Our results do not support an association of 5557G>A or
ivs38-8T>C variant, or any haplotype containing these in
the Finnish population, with bilateral breast cancer or
with increased breast cancer risk. Altogether, our results
suggest very minor effect, if any, of ATM genetic variants
on familial breast cancer in Southern Finland.
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